<DOC>
	<DOC>NCT00651469</DOC>
	<brief_summary>The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.</brief_summary>
	<brief_title>Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Female age 1445, with 10 to 100 comedones (noninflammatory lesions), 10 to 50 inflammatory lesions (papules or pustules), and not more than 35 nodules (&lt;5mm) on the face). Standard contraindications for use of combined oral contraceptives (class label) plus Subjects with acne and atopia, comedonal acne or acne conglobate, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts Use of comedogenic covering cream, comedogenic sunscreens, other sex hormone preparations or any other antiacne therapy (eg, light therapy, oleic acids, chemical pellings, mechanical extraction of comedones) Acne therapy with sex hormone preparations given over 3 months or longer and proved to be unsuccessful Preparations that have had an acneinducing effect, eg, iodinated or bromated drugs, tuberculostatics, lithium, Vitamin B1, B6, B12, D3, corticoids, ACTH, anabolics, quinine, disulfiram, methoxypsoralen, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Moderate Acne Vulgaris</keyword>
	<keyword>Acne</keyword>
</DOC>